IR@PKUHSC  > 北京大学第一临床医学院
学科主题临床医学
Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER study
Shi, Yuankai1,2; Li, Junling1,2; Zhang, Shucai3; Wang, Mengzhao4,5; Yang, Shujun6; Li, Ning7; Wu, Gang8; Liu, Wei9; Liao, Guoqing10; Cai, Kaican11; Chen, Liang′ an12; Zheng, Meizhen13; Yu, Ping14; Wang, Xiuwen15; Liu, Yunpeng16; Guo, Qisen17; Nie, Ligong18; Liu, Jiwei19; Han, Xiaohong1,2
刊名PLOS ONE
2015-11-23
DOI10.1371/journal.pone.0143515
10期:11
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Multidisciplinary Sciences
研究领域[WOS]Science & Technology - Other Topics
关键词[WOS]GROWTH-FACTOR RECEPTOR ; FEMALE NEVER-SMOKERS ; DRIVER MUTATIONS ; GENE-MUTATIONS ; KINASE DOMAIN ; OPEN-LABEL ; GEFITINIB ; SENSITIVITY ; FREQUENCY ; ERLOTINIB
英文摘要

Epidermal growth factor receptor (EGFR) mutations are the strongest response predictors to EGFR tyrosine kinase inhibitors (TKI) therapy, but knowledge of the EGFR mutation frequency on lung adenocarcinoma is still limited to retrospective studies. The PIONEER study (NCT01185314) is a prospective molecular epidemiology study in Asian patients with newly diagnosed advanced lung adenocarcinoma, aiming to prospectively analyze EGFR mutation status in IIIB/IV treatment-naive lung adenocarcinomas in Asia. We report the mainland China subset results. Eligible patients (similar to 20 yrs old, IIIB/IV adenocarcinoma and treatment-naive) were registered in 17 hospitals in mainland China. EGFR was tested for mutations by amplification refractory mutation system using biopsy samples. Demographic and clinical characteristics were collected for subgroup analyses. A total of 747 patients were registered. Successful EGFR mutation analysis was performed in 741, with an overall mutation rate of 50.2%. The EGFR active mutation rate is 48.0% (with 1.3% of combined active and resistance mutations). Tobacco use (>30 pack-year vs. 0-10 pack-year, OR 0.27, 95% CI: 0.17-0.42) and regional lymph nodes involvement (N3 vs. N0, OR 0.47, 95% CI: 0.29-0.76) were independent predictors of EGFR mutation in multivariate analysis. However, even in regular smokers, the EGFR mutation frequency was 35.3%. The EGFR mutation frequency was similar between diverse biopsy sites and techniques. The overall EGFR mutation frequency of the mainland China subset was 50.2%, independently associated with the intensity of tobacco use and regional lymph nodes involvement. The relatively high frequency of EGFR mutations in the mainland China subset suggest that any effort to obtain tissue sample for EGFR mutation testing should be encouraged.

语种英语
WOS记录号WOS:000365853900135
项目编号2008ZX09312 ; 2012ZX09303012-001 ; 200902002-1
资助机构AstraZeneca ; Chinese National Major Project for New Drug Innovation ; Research Special Fund for Public Welfare Industry of Health
引用统计
被引频次:33[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/56461
专题北京大学第一临床医学院
北京大学第一临床医学院_呼吸科
作者单位1.Peking Union Med Coll, Beijing 100005, Peoples R China
2.Chinese Acad Med Sci, Canc Hosp, Dept Med Oncol, Beijing 100021, Peoples R China
3.Peking Union Med Coll, Beijing Key Lab Clin Study Anticanc Mol Targeted, Beijing 100021, Peoples R China
4.Capital Med Univ, Beijing Chest Hosp, Dept Med Oncol, Beijing 1011429, Peoples R China
5.Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Respirat Med, Beijing 100005, Peoples R China
6.Henan Canc Hosp, Dept Med Oncol, Zhengzhou 450008, Henan Province, Peoples R China
7.Guangzhou Chest Hosp, Dept Med Oncol, Guangzhou 510095, Guangdong, Peoples R China
8.Huazhong Univ Sci & Technol, Ctr Canc, Union Hosp, Tongji Med Coll, Wuhan 430030, Hubei Province, Peoples R China
9.Hebei Med Univ, Dept Med Oncol, Hosp 4, Shijiazhuang 050035, Hebei Province, Peoples R China
10.Chinese Peoples Liberat Army, Hosp 309, Dept Med Oncol, Beijing 100091, Peoples R China
11.Southern Med Univ, Nanfang Hosp, Dept Med Oncol, Guangzhou 510515, Guangdong, Peoples R China
12.Chinese Peoples Liberat Army Gen Hosp, Dept Respirat Med, Beijing 100853, Peoples R China
13.Liaoning Canc Hosp, Dept Med Oncol, Shenyang 110042, Liaoning Provin, Peoples R China
14.Sichuan Canc Hosp, Dept Med Oncol, Chengdu 610041, Sichuan Provinc, Peoples R China
15.Shandong Univ, Qilu Hosp, Dept Med Oncol, Jinan 250012, Shandong, Peoples R China
16.China Med Univ, Dept Med Oncol, Hosp 1, Shenyang 110001, Liaoning Provin, Peoples R China
17.Shandong Canc Hosp, Dept Med Oncol, Jinan 250117, Shandong, Peoples R China
18.Peking Univ, Dept Respirat Med, Hosp 1, Beijing 100034, Peoples R China
19.Dalian Med Univ, Dept Med Oncol, Affiliated Hosp 1, Dalian 116011, Liaoning Provin, Peoples R China
推荐引用方式
GB/T 7714
Shi, Yuankai,Li, Junling,Zhang, Shucai,et al. Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER study[J]. PLOS ONE,2015,10(11).
APA Shi, Yuankai.,Li, Junling.,Zhang, Shucai.,Wang, Mengzhao.,Yang, Shujun.,...&Han, Xiaohong.(2015).Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER study.PLOS ONE,10(11).
MLA Shi, Yuankai,et al."Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER study".PLOS ONE 10.11(2015).
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Shi, Yuankai]的文章
[Li, Junling]的文章
[Zhang, Shucai]的文章
百度学术
百度学术中相似的文章
[Shi, Yuankai]的文章
[Li, Junling]的文章
[Zhang, Shucai]的文章
必应学术
必应学术中相似的文章
[Shi, Yuankai]的文章
[Li, Junling]的文章
[Zhang, Shucai]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。